BiomimX continues its growth and is expanding with larger offices within the Bio4Dreams headquarters at MIND – Milano Innovation District.

Founded in 2017, BiomimX is an innovative SME that develops human mini-organs on chips (organ-on-a-chip), a cutting-edge technology aimed at facilitating drug testing in the preclinical phase. Since 2019, BiomimX has been incubated by Bio4Dreams and is based at our headquarters in MIND, where it also utilizes the technologies and equipment of the SharedLabs^™.

The expansion into new spaces represents not only a physical but also a strategic evolution, allowing the company to host new professional profiles necessary to tackle upcoming challenges. In 2024 alone, BiomimX has reached significant milestones demonstrating its growing impact in the biotech sector, including participating in prestigious European consortia for advanced research projects, collaborating with biotech company Synartro to study the efficacy of an innovative osteoarthritis treatment, and strengthening its team with new young talents.

Horizon Europe projects: development of uBeat^® models for cardiac fibrosis and endometrium-on-a-chip

In 2024, BiomimX consolidated its presence in the European research landscape by participating in two prestigious consortia funded by the Horizon Europe program, within the Marie Skłodowska-Curie Actions (MSCA). These projects will expand BiomimX’s organ-on-a-chip portfolio based on its uBeat^® technology in two new research areas.

The first project, named MIRACLE, focuses on developing an immunocompetent model of cardiac fibrosis on a chip, designed for screening small molecules and advanced therapies. Through this initiative, BiomimX will contribute to improving therapeutic strategies for cardiometabolic diseases, an area of high global health relevance.

The second project, IMPLANTEU, is dedicated to creating a human endometrium model on a chip, with the goal of enhancing the understanding of human reproductive processes and improving the efficiency of embryo implantation. This project opens new perspectives in fertility research, a field of increasing interest to the scientific community.

Organ-on-a-chip for innovative osteoarthritis treatments

Another important milestone achieved by BiomimX involves the results of a study conducted in collaboration with biotech company Synartro on an innovative product for treating osteoarthritis, one of the leading causes of disability worldwide. The Swedish company relied on BiomimX to test the efficacy of its treatment on BiomimX’s osteoarthritis-on-a-chip model, which replicates the key characteristics of the disease in vitro, surpassing the limitations of traditional in vitro models and animal models.

The results of this study were published in Advanced Healthcare Materials, a leading journal in the field, and were accepted by Swedish regulatory authorities as part of an Investigational New Drug (IND) application, paving the way for the start of phase 1 and 2a clinical trials. This success not only confirms the potential of organ-on-a-chip technology but also opens new collaboration opportunities for the company in the therapeutic field.

Team growth: new expertise to face future challenges

BiomimX has also grown in terms of specialized expertise. Throughout the year, the company has strengthened its team with the addition of three new professionals. These experts bring innovative skills and fresh perspectives, enabling BiomimX to successfully tackle new challenges in organ-on-a-chip research.

The team’s growth reflects the company’s commitment to maintaining its competitive edge in a constantly evolving sector, relying on talent that can drive increasingly ambitious projects.

A fertile ecosystem for success

Throughout its journey, BiomimX has benefited from the Bio4Dreams ecosystem, which has provided valuable resources and opportunities to support its development. With access to shared research laboratories, the SharedLabs^™, the company has been able to apply its advanced technologies to the development of new biological models and in the context of important collaborations, successfully addressing the typical challenges of deep tech companies, such as accessibility and cost control of research equipment.

At the same time, the Bio4Dreams network has facilitated connections with strategic partners, suppliers, and potential customers, helping to expand BiomimX’s visibility in the pharmaceutical sector.

This supportive ecosystem has created fertile ground for innovation and synergies, but the achievements made are the result of the company’s continuous commitment and its ability to seize and make the most of these opportunities.

📗 Learn more about BiomimX and other companies in our portfolio.